An anthracycline antibiotic that has formula C27H29NO11.
Chemical ID:
MESH:D004317
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Doxorubicin results in increased activity of CASP8 protein]; [diphenyleneiodonium co-treated with mitoquinol co-treated with mitoquinone] inhibits the reaction [Doxorubicin results in increased activity of CASP8 protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Doxorubicin results in increased activity of CASP8 protein]; chloroquine diphosphate promotes the reaction [Doxorubicin inhibits the reaction [Thioacetamide results in decreased expression of CASP8 mRNA]]; coenzyme Q10 inhibits the reaction [Doxorubicin results in increased expression of CASP8 protein]; Cyclosporine inhibits the reaction [Doxorubicin results in increased activity of CASP8 protein]; Doxorubicin inhibits the reaction [Thioacetamide results in decreased expression of CASP8 mRNA]; Doxorubicin promotes the reaction [chloroquine diphosphate inhibits the reaction [Thioacetamide results in decreased expression of CASP8 mRNA]]; Doxorubicin results in increased cleavage of and results in increased activity of CASP8 protein; GPX1 protein inhibits the reaction [Doxorubicin results in increased activity of CASP8 protein]; pifithrin inhibits the reaction [Doxorubicin results in increased activity of CASP8 protein]; SIRT6 protein inhibits the reaction [Doxorubicin results in increased cleavage of CASP8 protein]; SOD2 protein inhibits the reaction [Doxorubicin results in increased activity of CASP8 protein]; TNF protein promotes the reaction [Doxorubicin results in increased cleavage of and results in increased activity of CASP8 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]; [CASP8 protein co-treated with CASP3 protein] affects the susceptibility to Doxorubicin; [Doxorubicin binds to TF protein] which results in increased activity of CASP8 protein; [Doxorubicin co-treated with 2,5,7,8-tetramethyl-2R-(4R,8R,12-trimethyltridecyl)chroman-6-yloxy acetic acid] results in increased cleavage of CASP8 protein; [Doxorubicin co-treated with Decitabine] results in increased cleavage of CASP8 protein; [Doxorubicin co-treated with FAS protein] results in increased activity of CASP8 protein; [Doxorubicin co-treated with Paclitaxel co-treated with Fluorouracil] results in increased activity of CASP8 protein; [Doxorubicin co-treated with Paclitaxel] results in increased activity of CASP8 protein; [Doxorubicin co-treated with Phellinus linteus extract] results in increased cleavage of and results in increased activity of CASP8 protein; [Doxorubicin co-treated with Selenium] promotes the reaction [FADD protein binds to CASP8 protein]; [Doxorubicin co-treated with Selenium] promotes the reaction [FAS protein binds to CASP8 protein]; [Indomethacin results in increased activity of CASP8 protein] which results in increased susceptibility to Doxorubicin; [Methotrexate results in increased expression of CASP8 protein] which results in increased susceptibility to Doxorubicin; [Oleanolic Acid results in increased susceptibility to Doxorubicin] which affects the expression of CASP8 mRNA; BCL2 protein inhibits the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]]; BCL2 protein inhibits the reaction [PI103 promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]]; CASP3 protein promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]; CCAR1 protein affects the reaction [Doxorubicin results in increased activity of CASP8 protein]; Doxorubicin results in increased cleavage of and results in increased activity of CASP8 protein; Doxorubicin results in increased expression of and results in increased cleavage of CASP8 protein; Folic Acid inhibits the reaction [Doxorubicin results in decreased expression of CASP8 mRNA]; LIG4 protein affects the reaction [Doxorubicin results in increased activity of CASP8 protein]; PI103 promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]; PRKDC protein affects the reaction [Doxorubicin results in increased activity of CASP8 protein]; TNFRSF10A protein affects the reaction [Doxorubicin results in increased activity of CASP8 protein]; TP53 protein promotes the reaction [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]]; TP53 protein promotes the reaction [PI103 promotes the reaction [Doxorubicin results in increased cleavage of CASP8 protein]]
